Fase II studie van sorafenib bij patienten met een gemetastaseerd niet-kleincellig bronchuscarcinoom die progressief zijn na voorafgaande behandeling met cisplatina bevattende chemotherapie waarvan de tumor een K-Ras mutatie bevat.

• Register: Netherlands Trial Register
• Last refreshed on: 28 April 2013
• Main ID: NTR2530
• Date of registration: 22/09/2010
• Primary sponsor: VU University Medical Center
• Public title: Fase II studie van sorafenib bij patienten met een gemetastaseerd niet-kleincellig bronchuscarcinoom die progressief zijn na voorafgaande behandeling met cisplatina bevattende chemotherapie waarvan de tumor een K-Ras mutatie bevat.
• Scientific title: A phase II study of sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) non-small lung cancer (NSCLC) with a K-Ras mutation. -
• Date of first enrolment: 1/6/2010
• Target sample size: 46
• Recruitment status: recruiting
• URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2530
• Study type: intervention
• Study design: Randomised: No; Masking: [default]; Control: Not applicable; Group: Parallel; Type: Single arm

Countries of recruitment

The Netherlands

Contacts

• Name: E.F. Smit

• Name: E.F. Smit

Key inclusion & exclusion criteria

Inclusion criteria: 1. Histologically advanced NSCLC stage IIIB or IV harbouring a K-RAS mutation;

2. Disease progression after at least 1 prior chemotherapy regimen that should include a platinum doublet;

3. Prior surgery and/or localized irradiation is permitted provided that the irradiated lesion is not the only measurable lesion;

4. Age > 18 years;

5. ECOG Performance Status of 0-2;

6. Life expectancy of at least 12 weeks;

7. Subjects with at least one uni-dimensional (for RECIST) measurable lesion. Lesions must be measured by CT-scan;

8. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:

A. Hemoglobin > 9.0 g/dl;

B. Absolute neutrophil count (ANC) >1,500/mm3;

C. Platelet count ≥ 100,000/μl;

D. Total bilirubin < 1.5 times the upper limit of normal;

E. ALT and AST < 2.5 x upper limit of normal (< 5 x upper limit of normal for patients with liver involvement of their cancer);

F. Alkaline phosphatase < 4 x ULN;

G. PT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with low molecular weight heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.];

H. Serum creatinine < 1.5 x upper limit of normal.

9. Written informed consent.
Exclusion criteria: Excluded medical conditions:

1. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arythmias requiring anti-arythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension;

2. History of HIV infection or chronic hepatitis B or C;

3. Active clinically serious infections (> grade 2 NCI-CTC version 3.0);

4. Symptomatic metastatic brain or meningeal tumors (unless the patient is > 1 months from definitive radiotherapy and off steroids);

5. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics);

6. History of organ allograft;

7. Patients with evidence or history of bleeding diasthesis;

8. Patients undergoing renal dialysis;

9. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.



Excluded therapies and medications, previous and concomitant:

1. Anticancer chemotherapy or immunotherapy during the study or within 3 weeks of study entry;

2. Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed). Major surgery within 3 weeks of start of study;

3. Autologous bone marrow transplant or stem cell rescue within 4 months of study;

4. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry. [G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator, however they may not be substituted for a required dose reduction.] [Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study];

5. Investigational drug therapy outside of this trial during or within 4 weeks of study entry;

6. Prior exposure to the study drugs;

7. Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial;

8. Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results;

9. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study;

10. Patients unable to swallow oral medications.

Age minimum:
Age maximum:
Gender:

Health Condition(s) or Problem(s) studied

Non small cell lung cancer (NSCLC)

Intervention(s)

Sorafenib 400 mg bd untill disease progression.

Primary Outcome(s)

Rate of non-progression at 6 weeks according to the RECISCT criteria.

Secondary Outcome(s)

Efficacy of sorafenib as determined by:

1. Duration of response;

2. Time to disease progression or death;

3. Survival.

Secondary ID(s)

NL30000.029.09 / 2009/305 ;

Source(s) of Monetary Support

VU University Medical Center